COMMUNIQUÉS West-GlobeNewswire
-
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
03/02/2026 -
Eleusis to Debut as the World’s First Legal Luxury Psychedelic Immersion
03/02/2026 -
Mark Mikhael, CEO of Olympia and Wesley Pharmaceuticals, Appointed to the Florida Board of Pharmacy by Governor Ron DeSantis
03/02/2026 -
Cynet Named a Strong Performer in 2026 Gartner Peer Insights™ “Voice of the Customer” for Endpoint Protection Platforms
03/02/2026 -
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/02/2026 -
Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026
03/02/2026 -
SRx Health Solutions Significantly Reduces Short Position of Cryptocurrency Portfolio Amidst Current Market Volatility
03/02/2026 -
Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
03/02/2026 -
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
03/02/2026 -
The Ensign Group Adds Real Estate and Operations in Texas
03/02/2026 -
RadNet Enters Indiana with Acquisition of Northwest Radiology
03/02/2026 -
TSC Life Receives FDA Clearance for Pediatric Use with Fluido® Compact System, a Blood & Fluid Warmer, in the U.S. and Canada
03/02/2026 -
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
03/02/2026 -
Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program
03/02/2026 -
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
03/02/2026 -
The Ensign Group Grows Operations in Arizona
03/02/2026 -
Peer-reviewed publication validates Cylinder Health savings
03/02/2026 -
The Ensign Group Obtains Real Estate and Operations in Texas
03/02/2026 -
Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran’s Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment
03/02/2026
Pages